Literature DB >> 111446

Suppression of the TSH response to TRH by thyroxine therapy in differentiated thyroid carcinoma patients.

B A Lamberg, M Rantanen, P Saarinen, K Liewendahl, A Sivula.   

Abstract

Absent response of serum thyrotrophin (TSH) after stimulation with 200 micrograms synthetic thyrotrophin-releasing hormone (TRH) was used as a criterion of adequate suppression of TSH in the treatment of thyroid carcinoma patients with thyroxine. The mean causing total suppression of the response was 223 micrograms of thyroxine per day. At this dose level about 40% of the patients had serum thyroxine concentrations above the upper reference interval and only 10% had elevated triiodothyronine concentrations. In some patients the TSH response to TRH varied between absent and low normal when tested at long intervals. The ideal dose of thyroxine is obviously slightly higher than the smallest one causing total suppression of the TSH response to TRH, i.e. about 250 micrograms a day. The individual dose must be found using the TRH stimulation test because serum thyroid hormone levels cannot be used as a guideline for adequate dosage. In some patients the thyroid remnant of apparently normal thyroid tissue was not totally suppressed although the thyroxine dose was definitely above the level causing suppression of the response to TRH.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 111446     DOI: 10.1530/acta.0.0910248

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  5 in total

1.  Nodular goiter: effects of surgery and thyroxine medication.

Authors:  K Westermark; C P Persson; H Johansson; F A Karlsson
Journal:  World J Surg       Date:  1986-06       Impact factor: 3.352

2.  Different rates of thyrotropin suppression after total body scan in patients with thyroid cancer: effect of regular doses of thyroxine and triiodothyronine.

Authors:  B Busnardo; F Bui; M E Girelli
Journal:  J Endocrinol Invest       Date:  1983-02       Impact factor: 4.256

3.  Different rates of thyrotropin suppression after total body scan in patients with thyroid cancer: effect of an optimal saturation regimen with thyroxine or triiodothyronine.

Authors:  B Busnardo; F Bui; M E Girelli
Journal:  J Endocrinol Invest       Date:  1983-12       Impact factor: 4.256

4.  TSH suppression in the management of thyroid nodules and thyroid cancer.

Authors:  O H Clark
Journal:  World J Surg       Date:  1981-01       Impact factor: 3.352

5.  Thyroxine uptake by human hepatoma cells from serum of patients submitted to long-term thyroxine suppressive therapy.

Authors:  L Bartalena; E Martino; M Falcone; A Pacchiarotti; A Pinchera
Journal:  J Endocrinol Invest       Date:  1988-10       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.